◆英語タイトル:Aeolus Pharmaceuticals Inc (AOLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013506
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Aeolus Pharmaceuticals Inc (Aeolus) is a biopharmaceutical company that is developing a platform of new compounds for use in cancer, infectious diseases, central nervous system (CNS) diseases, fibrosis and biodefense. The company’s lead product, AEOL 10150 is a broad catalytic antioxidant particularly designed to neutralize reactive oxygen and nitrogen species. AEOL-10150 compound is funded by the U.S. Government aimed at developing as a medical countermeasure against national security threats. The compound is being developed as a medical countermeasure against the delayed effects of acute radiation exposure and the pulmonary effects of acute radiation syndrome under an agreement with the Biomedical Advanced Research and Development Authority (BARDA), a division of the United States Department of Health and Human Services (HHS). Aeolus is headquartered in Mission Viejo, California, the US.
Aeolus Pharmaceuticals Inc (AOLS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Aeolus Pharma Enters into Research Agreement with Duke University 10
Licensing Agreements 11
Aeolus Pharma Enters into Licensing Agreement with National Jewish Health 11
Aeolus Pharma Enters into Licensing Agreement with University of Colorado 12
Equity Offering 13
Aeolus Pharma Plans to Raise Funds thorough Private Placement of Shares 13
Aeolus Pharma Raises USD6.8 Million in Private Placement of Units 14
Aeolus Pharma Completes Private Placement Of Units For US$3.2 Million 16
Aeolus Pharma Completes Private Placement Of Units For US$0.66 Million 17
Aeolus Pharmaceuticals Inc – Key Competitors 18
Aeolus Pharmaceuticals Inc – Key Employees 19
Aeolus Pharmaceuticals Inc – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
May 15, 2017: Aeolus Announces Second Quarter Financial Results for Fiscal Year 2017 21
Dec 21, 2016: Aeolus Announces Fiscal Year 2016 Financial Results 22
Aug 15, 2016: Aeolus Announces Third Quarter Fiscal Year 2016 Financial Results 23
May 16, 2016: Aeolus Announces Second Quarter Fiscal Year 2016 Financial Results and Investor Update Call 24
Feb 16, 2016: Aeolus Announces First Quarter Fiscal Year 2016 Financial Results 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27
List of Tables
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Aeolus Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Aeolus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Aeolus Pharma Enters into Research Agreement with Duke University 10
Aeolus Pharma Enters into Licensing Agreement with National Jewish Health 11
Aeolus Pharma Enters into Licensing Agreement with University of Colorado 12
Aeolus Pharma Plans to Raise Funds thorough Private Placement of Shares 13
Aeolus Pharma Raises USD6.8 Million in Private Placement of Units 14
Aeolus Pharma Completes Private Placement Of Units For US$3.2 Million 16
Aeolus Pharma Completes Private Placement Of Units For US$0.66 Million 17
Aeolus Pharmaceuticals Inc, Key Competitors 18
Aeolus Pharmaceuticals Inc, Key Employees 19
Aeolus Pharmaceuticals Inc, Subsidiaries 20